Intensive telephone-based cessation counseling results in improved smoking quit rates

WASHINGTON – Offering intensive, weekly telephone-based cessation counseling along with nicotine replacement for people who smoke and who were undergoing screening for lung cancer resulted in over a two-fold greater cigarette quit rate compared to people who received minimal counseling and nicotine replacement, according to results of a national, randomized trial conducted by investigators at Georgetown Lombardi Comprehensive Cancer Center and colleagues.

The findings appeared July 12, 2022, in JNCI and will be presented at the 2022 World Conference on Lung Cancer in Vienna, Austria, in August 2022.

People with a long-term smoking history are at high risk for lung cancer. Screening with computed tomography (CT) scans can potentially detect lung nodules early so that the disease can be treated in its less advanced stages. When undergoing CT screening, people are routinely offered cessation support, including counseling and nicotine replacement, to help them quit.

“Quitting smoking is very difficult and people who seek medication and support are more successful than those who try to quit on their own,” says Kathryn L. Taylor, Ph.D., professor in the Department of Oncology and a member of the Georgetown Lombardi Comprehensive Cancer Center’s Cancer Prevention and Control Program, and corresponding author of the study. “Importantly, making a quit attempt while undergoing lung screening may provide a boost to one’s motivation to stop smoking.”

The Georgetown Lung Screening, Tobacco, and Health trial randomized 818 people between 50 to 80 years of age with a 20-plus pack year smoking history (e.g., smoking two packs a day for a ten-year period equals 20 pack years). Enrollees at eight lung screening sites nationwide were randomly assigned to either intensive phone counseling of eight, 20-minute sessions along with up to eight weeks of nicotine patches, or three counseling sessions and two weeks of patches, which is similar to what many state tobacco quitlines currently offer people who call seeking assistance with quitting.

During the counseling sessions, tobacco treatment specialists discussed smoking-related goals, nicotine patch use, strategies to address triggers for smoking, readiness to quit, and confidence and motivation to quit.

“Tobacco treatment specialists met participants where they were in their readiness to quit – which ranged from not being ready to make any changes at the moment, but willing to talk about smoking, versus being very ready to quit and wanting specific ideas for making changes to their smoking habits,” notes Randi M. Williams, PhD, MPH, assistant professor in the Department of Oncology at Georgetown and second author of the study.

Self-reported 3-month quit rates were significantly higher in the intensive vs. minimal groups (14.3% vs. 7.9%). Importantly, quit rates that were verified by saliva strips or carbon monoxide tests were lower but with similar relative differences between groups (9.1% vs. 3.9%) of about two-to-one. Compared to the minimal arm, the intensive arm was more effective at spurring cessation among people with greater nicotine dependence (about a 3½ times greater benefit), normal screening results (over a 2½ times greater benefit), high engagement in counseling (a 3 times greater benefit) and patch use (a nearly 3 times greater use). Bolstering the value of intensive counseling for smoking cessation was a companion article appearing concurrently in JNCI Cancer Spectrum and led by researchers at the University of Michigan. The researchers found that even modest cessation rates achieved with intensive telephone counseling and nicotine replacement in the study group of people currently smoking and receiving lung screening led to savings in costs and lives compared to screening alone and would therefore be considered very cost-effective.

“Although the quit rates were modest overall, when comparing 3-month and12-month outcomes, both groups maintained the quit rates over time,” says Taylor. “Our next step is a planned trial with enhanced interventions and strategies to increase enrollment and treatment engagement among people undergoing lung screening in a large healthcare system, including underserved racial and ethnic minority groups, uninsured patients, and people not ready to quit.”

###

In addition to Taylor and Williams, the other authors from Georgetown include Tengfei Li, George Luta, Laney Smith, Kimberly M. Davis, Tania Lobo, Jeanne Mandelblatt, Jinani Jayasekera and Eric D. Anderson. Cassandra Stanton is at Westat, Rockville, Maryland; Raymond Niaura and David Abrams are at New York University, New York; Rafael Meza, Jihyoun and Jeonand Pianpian Cao are at the University of Michigan, Ann Arbor.

This study was supported by National Cancer Institute (NCI) grants R01CA207228 and R01CA207228-S1 as part of the NCI’s Smoking Cessation at Lung Examination (SCALE) collaboration.

The authors report having no personal financial interests related to the study. 

About Georgetown Lombardi Comprehensive Cancer Center
Georgetown Lombardi Comprehensive Cancer Center is designated by the National Cancer Institute (NCI) as a comprehensive cancer center. A part of Georgetown University Medical Center, Georgetown Lombardi is the only comprehensive cancer center in the Washington D.C. area. It serves as the research engine for MedStar Health, Georgetown University’s clinical partner. Georgetown Lombardi is also an NCI recognized consortium with John Theurer Cancer Center/Hackensack Meridian Health in Bergen County, New Jersey. The consortium reflects an integrated cancer research enterprise with scientists and physician-researchers from both locations. Georgetown Lombardi seeks to improve the diagnosis, treatment, and prevention of cancer through innovative basic, translational and clinical research, patient care, community education and outreach to service communities throughout the Washington region, while its consortium member John Theurer Cancer Center/Hackensack Meridian Health serves communities in northern New Jersey. Georgetown Lombardi is a member of the NCI Community Oncology Research Program (UG1CA239758). Georgetown Lombardi is supported in part by a National Cancer Institute Cancer Center Support Grant (P30CA051008). Connect with Georgetown Lombardi on Facebook (Facebook.com/GeorgetownLombardi) and Twitter (@LombardiCancer).